Patents by Inventor Michelle L. Hastings

Michelle L. Hastings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2 (LRRK2) For The Treatment Of Parkinsons Disease
    Publication number: 20170137826
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 18, 2017
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for usher syndrome
    Patent number: 9556434
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: January 31, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L Hastings
  • ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH CYSTIC FIBROSIS
    Publication number: 20160244767
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Application
    Filed: February 17, 2016
    Publication date: August 25, 2016
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. HASTINGS
  • Antisense compounds targeting genes associated with usher syndrome
    Patent number: 9353371
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an Usher transcript. Certain such compounds are useful for hybridizing to an Usher transcript, including but not limited, to an Usher transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the Usher transcript. In certain such embodiments, the Usher transcript includes a mutation that results in cryptic splicing and hybridization of the oligonucleotide results in a decrease in the amount of cryptic splicing. In certain embodiments, such compounds are used to treat Usher Syndrome.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: May 31, 2016
    Assignees: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Michelle L. Hastings, Frank Rigo, C. Frank Bennett
  • ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME
    Publication number: 20150315590
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Application
    Filed: May 6, 2015
    Publication date: November 5, 2015
    Inventor: Michelle L. HASTINGS
  • ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME
    Publication number: 20140243388
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 28, 2014
    Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
    Inventor: Michelle L. Hastings
  • ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH USHER SYNDROME
    Publication number: 20140114057
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an Usher transcript. Certain such compounds are useful for hybridizing to an Usher transcript, including but not limited, to an Usher transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the Usher transcript. In certain such embodiments, the Usher transcript includes a mutation that results in cryptic splicing and hybridization of the oligonucleotide results in a decrease in the amount of cryptic splicing. In certain embodiments, such compounds are used to treat Usher Syndrome.
    Type: Application
    Filed: May 2, 2012
    Publication date: April 24, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michelle L. Hastings, Frank Rigo, C. Frank Bennett
  • Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
    Patent number: 8648053
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: February 11, 2014
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME
    Publication number: 20130035367
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Application
    Filed: May 1, 2012
    Publication date: February 7, 2013
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME
    Publication number: 20120165389
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Application
    Filed: October 20, 2011
    Publication date: June 28, 2012
    Inventor: Michelle L. Hastings